U.S. Stem Cell, Inc.
↗Sunrise, Florida, United States
U.S. Stem Cell, Inc. is a biotechnology company engaged in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, vascular diseases, and autoimmune conditions. The company was founded in 1999 as Bioheart, Inc. and rebranded to U.S. Stem Cell, Inc. in October 2015. Beyond pharmaceutical development, the company operates a regenerative medicine business including physician and patient training services, cell collection and treatment kits for humans and animals, and operates a network of cell therapy clinics. The company's core focus has been developing MyoCell, a muscle stem cell therapy for cardiac applications, and AdipoCell, a patient-derived adipose-derived stem cell therapy. The company also operates Vetbiologics, a veterinary regenerative medicine division providing stem cell therapies for companion animals and equine patients.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Regenerative Medicine, Cell Therapy
SIZE & FINANCIALS
Employees:11-50
Revenue:<$1M
Founded:1999
Ownership:public
Status:operating
FUNDING
Stage:Commercial
Total Raised:$145M+
Investors:General American Capital Partners
STOCK
Exchange:OTC Markets
Ticker:USRM
Market Cap:$662K
PIPELINE
Stage:Clinical Development
Lead Drug Stage:Phase II/III
Modalities:Autologous cell therapy, Muscle-derived stem cells, Adipose-derived stem cells, Stromal vascular fraction (SVF)
Active Trials:3
Trial Phases:Phase 1: 1 | Phase 2: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Vetbiologics (veterinary regenerative medicine), US Stem Cell Training, US Stem Cell Clinic, LLC (33.3% investment)
Key Partnerships:Advanced Stem Cell Rx (strategic alliance)
COMPETITION
Position:Emerging/Challenged
Competitors:Vertex Pharmaceuticals (stem cell-derived islet cell therapies for type 1 diabetes), BlueRock Therapeutics/Bayer (allogeneic pluripotent stem cell therapeutics), Fate Therapeutics (stem cell and CAR-T therapies), Century Therapeutics (adult stem cell cancer therapies), Magenta Therapeutics (stem cell biology for transplant medicine), Regenexx (orthopedic stem cell therapies), Mesoblast Ltd (allogeneic MSC therapies)
LEADERSHIP
Key Executives:
Mike Tomas - President, CEO, CFO, and Director
Dr. Kristin Comella - Chief Science Officer
Scientific Founders:Howard Leonhardt (Founder (Bioheart, Inc.)), Dr. William P. Murphy Jr. (Co-Founder/Board Member)
Board Members:Mike Tomas (President, CEO, CFO, and Director), Dr. William P. Murphy Jr. (Chairman Emeritus), Mark Borman (Board Member)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with U.S. Stem Cell, Inc.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.